Epix initiate second Phase IIb trial of 5HT4 agonist PRX-03140 for Alzheimer’s disease « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
June 2008

M T W T F S S

« May Jul »

1

2 3 4 5 6 7 8

9 10 11 12 13 14 15

16 17 18 19 20 21 22

23 24 25 26 27 28 29

30

Epix initiate second Phase IIb trial of 5HT4 agonist PRX-03140 for Alzheimer’s disease

Posted on June 11, 2008 by crimsoncanary

EPIX Pharmaceuticals have initiated a second Phase IIb trial of its 5-HT4 agonist PRX03140 in Alzheimers disease. The trial will evaluate PRX-03140 when adminstered as a monotherapy and in combination with donepezil

Filed under: gpcr | Tagged: 5-HT4, 5HT4, agonist, Epix, gpcr, phase II

« Researchers from the Italy publish series of Pyrrolidinylfuran Muscarinic M2 agonists Novel series of sst2-Selective Somatostatin Antagonists »

Leave a Reply